Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer | Zendy

Joseph A. Sparano | Zendy; Robert J. Gray | Zendy; Peter M. Ravdin | Zendy; Della Makower | Zendy; Kathleen I. Pritchard | Zendy; Kathy S. Albain | Zendy; Daniel F. Hayes | Zendy; Charles E. Geyer | Zendy; Elizabeth Claire Dees | Zendy; Matthew P. Goetz | Zendy; John A. Olson | Zendy; Tracy Lively | Zendy; Sunil Badve | Zendy; Thomas J. Saphner | Zendy; Lynne I. Wagner | Zendy; Timothy J. Whelan | Zendy; Matthew J. Ellis | Zendy; Soonmyung Paik | Zendy; William C. Wood | Zendy; Maccon Keane | Zendy; Henry Gómez | Zendy; Pavan S. Reddy | Zendy; Timothy F. Goggins | Zendy; Ingrid A. Mayer | Zendy; Adam Brufsky | Zendy; Deborah Toppmeyer | Zendy; Virginia Kaklamani | Zendy; Jeffrey L. Berenberg | Zendy; Jeffrey S. Abrams | Zendy; George W. Sledge | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer

Author(s) -

Joseph A. Sparano,

Robert J. Gray,

Peter M. Ravdin,

Della Makower,

Kathleen I. Pritchard,

Kathy S. Albain,

Daniel F. Hayes,

Charles E. Geyer,

Elizabeth Claire Dees,

Matthew P. Goetz,

John A. Olson,

Tracy Lively,

Sunil Badve,

Thomas J. Saphner,

Lynne I. Wagner,

Timothy J. Whelan,

Matthew J. Ellis,

Soonmyung Paik,

William C. Wood,

Maccon Keane,

Henry Gómez,

Pavan S. Reddy,

Timothy F. Goggins,

Ingrid A. Mayer,

Adam Brufsky,

Deborah Toppmeyer,

Virginia Kaklamani,

Jeffrey L. Berenberg,

Jeffrey S. Abrams,

George W. Sledge

Publication year - 2019

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1904819

Subject(s) - breast cancer , medicine , oncology , adjuvant , adjuvant therapy , adjuvant chemotherapy , chemotherapy , cancer

The use of adjuvant chemotherapy in patients with breast cancer may be guided by clinicopathological factors and a score based on a 21-gene assay to determine the risk of recurrence. Whether the level of clinical risk of breast cancer recurrence adds prognostic information to the recurrence score is not known.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research